Analyst Price Targets — TLSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 12:41 pm | — | Lake Street | $8.00 | $2.37 | TheFly | TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street |
| November 15, 2024 12:04 pm | William Plovanic | Canaccord Genuity | $11.00 | $4.11 | StreetInsider | TriSalus Life Sciences, Inc. (TLSI) PT Lowered to $11 at Canaccord Genuity |
| September 16, 2024 6:06 am | Suraj Kalia | Oppenheimer | $10.00 | $4.52 | StreetInsider | Oppenheimer Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform, PT $10 |
| July 2, 2024 5:51 am | William Plovanic | Canaccord Genuity | $12.00 | $5.33 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI) |
Latest News for TLSI
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.
TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressure-enabled delivery technology for solid-tumor treatments.
TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TLSI.
U.S. House Trading
No House trades found for TLSI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.